Benjamin Walbaum, Medical Oncologist at Pontifical Catholic University of Chile, shared a post on LinkedIn:
“Breast Cancer Weekly Update | Feb 16–23, 2026
Here are my key takeaways from last week’s most relevant publications:
- TRAIN-3 (HER2+ early BC) – MRI-guided early surgery after 1–3 cycles maintained excellent 3-year EFS while reducing toxicity.
The Lancet Oncology - BRCA1/2, PALB2 in HR+ MBC – Germline BRCA/PALB2 mutations were associated with shorter PFS on first-line ET + CDK4/6 inhibitors.
The Breast - SONIA Trial (CDK4/6 sequencing) – First-line vs second-line CDK4/6 inhibition showed no OS difference in advanced HR+ disease.
JAMA Oncology - Tamoxifen – 20-year data (Luminal A/B) – Long-term benefit persists in both subtypes, with distinct temporal patterns of recurrence reduction.
Journal of the National Cancer Institute - J-START (Screening 40–49 years) – Adding ultrasound to mammography reduced cumulative incidence of advanced breast cancer in younger women.
The Lancet - Personalized mRNA Vaccine in TNBC – Neoantigen vaccines induced durable multi-epitope T-cell responses with encouraging long-term relapse-free outcomes.
Nature - LLMs vs St. Gallen Consensus – Deep LLMs achieved moderate concordance with expert panel decisions in early breast cancer scenarios.
Annals of Surgical Oncology - AI-induced Arthralgia – Symptom burden remains a major driver of endocrine therapy nonadherence in early HR+ disease.
JNCCN - PROMETEO (T-VEC + atezolizumab) – In residual disease post-NAC, when adding intratumoral T-VEC plus Atezo, 26.9% achieved RCB 0–I with clear immune activation and TIL increase.
Nature Communications - ESMO EnLiST Framework – Standardized definitions of Lines of Therapy will improve trial design and real-world data harmonization.
Annals of Oncology.”
Other articles featuring Benjamin Walbaum on OncoDaily.
